Fingerprint Fingerprint is based on mining the text of the persons scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 5 Similar Profiles
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences
Interferon-alpha Medicine & Life Sciences
Philadelphia Chromosome Medicine & Life Sciences
Cytogenetics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Leukemia, Myeloid, Chronic Phase Medicine & Life Sciences
Mesylates Medicine & Life Sciences
Bone Marrow Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 1997 2026

Research Output 1979 2017

Exome
Primary Myelofibrosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transcriptome
Neoplasms

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias

Cortes, J. E., Gambacorti-Passerini, C., Kim, D. W., Kantarjian, H. M., Lipton, J. H., Lahoti, A., Talpaz, M., Matczak, E., Barry, E., Leip, E., Brümmendorf, T. H. & Khoury, H. J. 2017 In : Clinical Lymphoma, Myeloma and Leukemia.

Research output: Contribution to journalArticle

Induction of p53 suppresses chronic myeloid leukemia

Peterson, L. F., Lo, M. C., Liu, Y., Giannola, D., Mitrikeska, E., Donato, N. J., Johnson, C. N., Wang, S., Mercer, J. & Talpaz, M. Jan 13 2017 In : Leukemia and Lymphoma. p. 1-14 14 p.

Research output: Contribution to journalArticle

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Philadelphia Chromosome
Myeloid Cells
Cell Cycle
1 Citations

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Harrison, C. N., Schaap, N., Vannucchi, A. M., Kiladjian, J. J., Tiu, R. V., Zachee, P., Jourdan, E., Winton, E., Silver, R. T., Schouten, H. C., Passamonti, F., Zweegman, S., Talpaz, M., Lager, J., Shun, Z. & Mesa, R. A. Jul 1 2017 In : The Lancet Haematology. 4, 7, p. e317-e324

Research output: Contribution to journalArticle

Janus Kinase 2
Primary Myelofibrosis
Multicenter Studies
Spleen
Splenomegaly
5 Citations

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Verstovsek, S. , Mesa, R. A. , Gotlib, J. , Gupta, V. , DiPersio, J. F. , Catalano, J. V. , Deininger, M. W. N. , Miller, C. B. , Silver, R. T. , Talpaz, M. , Winton, E. F. , Harvey, J. H. , Arcasoy, M. O. , Hexner, E. O. , Lyons, R. M. , Paquette, R. , Raza, A. , Jones, M. , Kornacki, D. , Sun, K. & 1 others Kantarjian, H. Feb 22 2017 In : Journal of Hematology and Oncology. 10, 1, p. 1-14 14 p.

Research output: Contribution to journalArticle

Primary Myelofibrosis
Placebos
Spleen
Safety
Splenomegaly